New frontiers for cardiac risk assessment: C-reactive protein

Consultant Pharmacist

Volumn 21, Issue 3, 2006, Pages 188-206

  Martin, Caren McHenry ^a   Almond, Jina ^a  

^a NONE

Author keywords

Atherosclerosis; C reactive protein; Cardiac risk assessment; Cholesterol; Heart disease; Inflammation; Myocardial infarction; Statin

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ABCIXIMAB; ACETYLSALICYLIC ACID; ANTILIPEMIC AGENT; APOLIPOPROTEIN B; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CHOLESTEROL; FIBRINOGEN RECEPTOR ANTAGONIST; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERLEUKIN 6; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; PIOGLITAZONE; PRAVASTATIN; ROSIGLITAZONE; ROSUVASTATIN; SIMVASTATIN; TIROFIBAN;

ATHEROSCLEROTIC PLAQUE; CARDIOVASCULAR RISK; CLINICAL TRIAL; DIET THERAPY; DOSE RESPONSE; HIGH RISK PATIENT; HUMAN; INFLAMMATION; ISCHEMIC HEART DISEASE; KINESIOTHERAPY; MASS SCREENING; PRACTICE GUIDELINE; REVIEW; RISK ASSESSMENT; RISK FACTOR; TREATMENT PLANNING;

EID: 33645064521     PISSN: 08885109     EISSN: None     Source Type: Journal    
DOI: 10.4140/tcp.n.2006.188     Document Type: Review

References (28)

1. American Heart Association. Dallas: Inflammation, heart disease and stroke: The role of C-Reactive protein. [cited 2006 Feb 14]. Available from: www.americanheart.org/presenter.jhtml?identifier=4648 〈http://www. americanheart.org/presenter.jhtml?identifier=4648〉.
2. Ridker PM, Cushman M, Stampfer MJ et al. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 1997;336:973-9.
3. Ridker P. High-sensitivity c-reactive protein and cardiovascular risk: rationale for screening and primary prevention. Am J Cardiol 2003;92(suppl):17K-22K.
4. Ridker PM, Hennekens CH Buring, JE et al. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Eng J Med 2000;342:836-43.
5. Libby P, Ridker P. Inflammation and atherosclerosis: role of c-reactive protein in risk assessment. Am J Med 2004;116(6A):S9-S16.
6. Ridker P. High-sensitivity c-reactive protein, inflammation, and cardiovascular risk: from concept to clinical practice to clinical benefit. Am Heart J 2004;148:S19-S26.
7. Ford E, Ajani U, Mokdad AH, for the National Health and Nutrition Examination. The metabolic syndrome and concentrations of c-reactive protein among U.S. Youth. Diabetes Care 2005;28:878-81.
8. Ridker P. Rosuvastatin in the primary prevention of cardiovascular disease among patients with low levels of low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein. Circulation 2003;108:2292-7.
9. Freeman D, Norris J, Caslake M et al. C-reactive protein is an independent predictor of risk for the development of diabetes in the West of Scotland coronary prevention study. Diabetes 2002;51:1596-600.
10. Cushman M, Arnold A, Psaty B et al. C-reactive protein and the 10-year incidence of coronary heart disease in older men and women: the cardiovascular health study. Circulation, 2005;112:25-31.
11. Mascotti L, Ceccarelli E, Forconi S et al. Prognostic role of c-reactive protein in very old patients with acute ischaemic stroke. J Intern Med 2005;258:145-52.
12. Yin, W, Chen J et al. Independent prognostic value of elevated high-sensitivity c-reactive protein in chronic heart failure. Am Heart J 2004;145:931-8.
13. Plenge J, Hernandez TL, Weil KM. Simvastatin lowers C-reactive protein within 14 days: an effect independent of low-density lipoprotein cholesterol reduction. Circulation 2002;106:1447-52.
14. Ridker P, Rifai N, Clearfield M et al. for the Air Force/Texas Coronary Atherosclerosis Prevention Study Investigators. Measure of c-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. N Engl J Med 2001;344:1959-65.
15. Ridker P, Cannon C, Morrow D et al. C-reactive protein levels and outcomes after statin therapy. N Engl J Med 2005;352:20-8.
16. De Lemos J, Blazing M, Wiviott S et al. Early intensive versus a delayed conservative simvastatin strategy in patients with acute coronary syndromes. JAMA 2004;292:1307-16.
17. Nissen S, Tuzcu E, Schoenhagen P et al. Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease. N Engl J Med 2005;352:29-38.
18. Beattie M, Shlipak M, Liu H et al. C-reactive protein and ischemia in users and nonusers of beta-blockers and statins. Circulation 2003;107:245-50.
19. Heart Protection Study Collaborative Group. MRC/BHF heart protection study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomized placebo controlled trial. Lancet 2002;360:7-22.
20. Ikonomidis I, Andreotti F, Economou E et al. Increased proinflammatory cytokines in patients with stable angina and their reduction by aspirin. Circulation 1999;100:793-8.
21. Lincoff A, Kereiakes D, Mascelli M et al. Abciximab suppresses the rise in levels of circulating inflammatory markers after percutaneous coronary revascularization. Circulation 2001;104:163-7.
22. Pfutzner A, Marx N, Lubben G et al. Improvement of cardiovascular risk markers by pioglitazone is independent from glycemic control. J Am Coll Cardiol 2005;45:1925-31.
23. Bailey C. Treating insulin resistance in type 2 diabetes with metformin and thiazolidinediones. Diabetes Obes Metab 2005;7:675-91.
24. Bell D. Advantages of a third-generation beta-blocker in patients with diabetes mellitus. Am J Cardiol 2004;93 (suppel):49B-52B.
25. Jenkins D, Kendall C, Marchie A et al. Effects of a dietary portfolio of cholesterol lowering foods vs. lovastatin on serum lipids and c-reactive protein. JAMA 2003;290:502.
26. Erlinger T, Miller E, Charleston J et al. Inflammation modifies the effects of a reduced-fat low-cholesterol diet on lipids: results from the DASH-Sodium Trial. Circulation 2003;108:150-4.
27. Lakka TA, Lakka HM, Rankinen T et al. Effect of exercise training on plasma levels of C-reactive protein in healthy adults: the HERITAGE Family Study. Eur Heart J 2005;26:2018-25.
28. Pearson, TA, Mensah, GA, Alexander RW et al. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 2003;107:499-511.